uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share.
Shares of American Tower (AMT 6.68%) looked down on Wall Street from a lofty position on Tuesday. The owner and operator of wireless networking and broadcast infrastructure posted stellar fourth-quarter results in the early morning.
AMT's Q4 results reflect a year-over-year rise in revenues, led by property and service operations segment revenues. Strong organic tenant billing growth aids results.
The headline numbers for American Tower (AMT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
American Tower (AMT 0.23%), a leader in wireless communication infrastructure, announced its financial results for the fourth quarter of 2024 on February 25, 2025.
I screened for high-quality, competitively advantaged REITs to deliver 29% annualized returns in 2025; the portfolio is on target with a 5.4% YTD return. Top performers include Terreno (+13.5%), EastGroup (+12.7%), and Realty Income (+7.9%), while Ryman Hospitality (-4.6%) and Alexandria (-0.7%) lag. Strong balance sheets and strategic market positioning are key factors for REITs like EastGroup, Terreno, and Rexford, supporting my buy and strong buy ratings.
uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025.
Evaluate the expected performance of American Tower (AMT) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
I created a diversified REIT portfolio for my mom, aiming for consistent income and optimized total returns, with an average dividend yield of 4.9%. Key REITs include Invitation Homes, Apple Hospitality, Realty Income, Healthpeak, Mid-America, Sun Communities, American Tower, VICI Properties, Prologis, and Ladder Capital. Each REIT was selected based on strong financial metrics, growth potential, and solid dividend yields, ensuring resilience and steady income.
REITs are available in more than 20 different property sectors. Some are more attractive than others. Here are three of my favorite REIT property sectors to buy in 2025.
Starlink, a SpaceX subsidiary, aims to revolutionize global connectivity with 7,000 satellites and over 4 million subscribers, despite challenges like limited bandwidth and high costs. American Tower and Crown Castle are key players in communications infrastructure, with AMT showing strong growth and CCI facing potential dividend cuts. Cell towers and satellites complement each other, with towers providing high-capacity, low-latency communication and satellites extending coverage to remote areas.
American Tower (AMT) reachead $189.88 at the closing of the latest trading day, reflecting a +0.55% change compared to its last close.